ZyVersa Therapeutics Inc (ZVSA)
1.18
-0.05
(-3.87%)
USD |
NASDAQ |
Jan 08, 16:00
1.18
0.00 (0.00%)
After-Hours: 20:00
ZyVersa Therapeutics SG&A Expense (Quarterly): 1.834M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| MetaVia Inc | 1.742M |
| Dermata Therapeutics Inc | 0.8243M |
| Cognition Therapeutics Inc | 3.071M |
| NovaBay Pharmaceuticals Inc | 2.65M |
| Palatin Technologies Inc | 2.021M |